This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. ASLN, CWBR, EVFM, ATXI, OGEN, PTPI, TRVN, PBLA, ATHX, and HEPAShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Avenue Therapeutics (ATXI), Oragenics (OGEN), Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Athersys (ATHX), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Its Competitors ASLAN Pharmaceuticals CohBar Evofem Biosciences Avenue Therapeutics Oragenics Petros Pharmaceuticals Trevena Panbela Therapeutics Athersys Hepion Pharmaceuticals Conatus Pharmaceuticals (NASDAQ:CNAT) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Is CNAT or ASLN more profitable? ASLAN Pharmaceuticals has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Conatus Pharmaceuticals-52.42% -48.22% -39.32% ASLAN Pharmaceuticals N/A -8,454.87%-121.60% Does the media prefer CNAT or ASLN? In the previous week, Conatus Pharmaceuticals' average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score. Company Overall Sentiment Conatus Pharmaceuticals Neutral ASLAN Pharmaceuticals Neutral Do institutionals & insiders hold more shares of CNAT or ASLN? 15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 11.3% of Conatus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CNAT or ASLN? Conatus Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Which has preferable earnings and valuation, CNAT or ASLN? Conatus Pharmaceuticals has higher revenue and earnings than ASLAN Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/AASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03 SummaryConatus Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$10K$780.12M$5.46B$8.92BDividend YieldN/A4.84%5.24%4.04%P/E Ratio0.001.2927.0120.12Price / Sales0.00230.51380.1493.34Price / CashN/A23.4426.2128.59Price / Book0.006.137.995.57Net Income-$11.39M-$27.85M$3.16B$248.40M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.00flatN/A-99.9%$10K$21.72M0.0030ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010EVFMEvofem Biosciences0.5922 of 5 stars$0.01+1.0%N/A+3.1%$1.18M$11.39M-0.02120ATXIAvenue Therapeutics2.1086 of 5 stars$0.35+74.4%N/A-90.5%$1.11MN/A0.024Gap UpOGENOragenics0.2165 of 5 stars$1.55-59.4%N/A-94.9%$1.11M$40K-0.225Gap DownHigh Trading VolumePTPIPetros Pharmaceuticals0.6477 of 5 stars$0.03-2.4%N/A-99.7%$1.02M$5.11M-0.0120Gap UpTRVNTrevena1.6043 of 5 stars$1.05-5.4%$5.00+376.2%-83.2%$1.01M$443K-0.0240Gap DownHigh Trading VolumePBLAPanbela Therapeutics0.0921 of 5 stars$0.19-18.2%N/A-57.1%$921KN/A0.006Gap DownHigh Trading VolumeATHXAthersysN/AN/AN/AN/A$833K$146K0.0024HEPAHepion Pharmaceuticals0.6868 of 5 stars$0.07-14.9%N/A-99.9%$744KN/A-0.0220Gap Down Related Companies and Tools Related Companies ASLAN Pharmaceuticals Competitors CohBar Competitors Evofem Biosciences Competitors Avenue Therapeutics Competitors Oragenics Competitors Petros Pharmaceuticals Competitors Trevena Competitors Panbela Therapeutics Competitors Athersys Competitors Hepion Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNAT Stock Alerts